Age of Parkinson's disease onset as a predictor for the development of dyskinesia
Identifieur interne : 001E60 ( Main/Exploration ); précédent : 001E59; suivant : 001E61Age of Parkinson's disease onset as a predictor for the development of dyskinesia
Auteurs : Stephen Ku [États-Unis] ; Graham A. Glass [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-07-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adult, Age Factors, Age of Onset, Age of onset, Aged, Aged, 80 and over, Dyskinesia, Dyskinesia, Drug-Induced (diagnosis), Dyskinesia, Drug-Induced (etiology), Dyskinesia, Drug-Induced (mortality), Female, Humans, Kaplan-Meier Estimate, Levodopa (adverse effects), Longitudinal Studies, Male, Middle Aged, Nervous system diseases, Parkinson disease, Parkinson's disease, Parkinsonian Disorders (drug therapy), Parkinsonian Disorders (mortality), Predictive Value of Tests, Proportional Hazards Models, Risk Factors, age of onset, dyskinesia.
- MESH :
- chemical , adverse effects : Levodopa.
- diagnosis : Dyskinesia, Drug-Induced.
- drug therapy : Parkinsonian Disorders.
- etiology : Dyskinesia, Drug-Induced.
- mortality : Dyskinesia, Drug-Induced, Parkinsonian Disorders.
- Adult, Age Factors, Age of Onset, Aged, Aged, 80 and over, Female, Humans, Kaplan-Meier Estimate, Longitudinal Studies, Male, Middle Aged, Predictive Value of Tests, Proportional Hazards Models, Risk Factors.
Abstract
The risk of developing levodopa‐associated dyskinesia is known to vary inversely with the age of Parkinson's disease onset. This study quantifies dyskinesia risks for different Parkinson's onset ages in a patient population treated at the Parkinson's Disease Research, Education, and Clinical Center at the San Francisco Veterans Affairs Medical Center. Medical records were reviewed to determine age of Parkinson's onset, medication history, and dyskinesia onset. Dyskinesia risks were determined by using Kaplan‐Meier analysis. Cox proportional hazard models were used to compare age groups and to perform multivariate modeling. This study included 109 patients with Parkinson's, 105 of whom had onset of symptoms after 1989. At 5 years of levodopa treatment, the dyskinesia risk for patients with onset age 40–49 was 70%, decreasing to 42% for onset ages 50–59, 33% for onset ages 60–69, and 24% for onset ages 70–79. Pairwise comparisons between the 40–49 age group and the other age groups were statistically significant in time‐to‐event models. After 5 years of levodopa treatment, dyskinesia risks became uniformly high regardless of age of onset. These results suggest it is appropriate to use different baseline dyskinesia risks in clinical decision‐making for patients on the basis of their ages of onset. However, the most significant difference occurs between ages 40–49 and ages 50–79, and if more than 5 years of levodopa therapy are anticipated, dyskinesia risk may have less utility when deciding upon Parkinson's therapy. Drug studies for Parkinson's disease should also take age of Parkinson's onset into account when analyzing dyskinesia outcomes. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23068
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001359
- to stream Istex, to step Curation: 001359
- to stream Istex, to step Checkpoint: 000B39
- to stream PubMed, to step Corpus: 001876
- to stream PubMed, to step Curation: 001876
- to stream PubMed, to step Checkpoint: 001A50
- to stream Ncbi, to step Merge: 002B26
- to stream Ncbi, to step Curation: 002B26
- to stream Ncbi, to step Checkpoint: 002B26
- to stream Main, to step Merge: 002296
- to stream PascalFrancis, to step Corpus: 000A22
- to stream PascalFrancis, to step Curation: 002297
- to stream PascalFrancis, to step Checkpoint: 000C12
- to stream Main, to step Merge: 002799
- to stream Main, to step Curation: 001E60
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Age of Parkinson's disease onset as a predictor for the development of dyskinesia</title><author><name sortKey="Ku, Stephen" sort="Ku, Stephen" uniqKey="Ku S" first="Stephen" last="Ku">Stephen Ku</name></author><author><name sortKey="Glass, Graham A" sort="Glass, Graham A" uniqKey="Glass G" first="Graham A." last="Glass">Graham A. Glass</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F598433AF0D9202088154346E0D8C4376AA41E73</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23068</idno><idno type="url">https://api.istex.fr/document/F598433AF0D9202088154346E0D8C4376AA41E73/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001359</idno><idno type="wicri:Area/Istex/Curation">001359</idno><idno type="wicri:Area/Istex/Checkpoint">000B39</idno><idno type="wicri:doubleKey">0885-3185:2010:Ku S:age:of:parkinson</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:20310028</idno><idno type="wicri:Area/PubMed/Corpus">001876</idno><idno type="wicri:Area/PubMed/Curation">001876</idno><idno type="wicri:Area/PubMed/Checkpoint">001A50</idno><idno type="wicri:Area/Ncbi/Merge">002B26</idno><idno type="wicri:Area/Ncbi/Curation">002B26</idno><idno type="wicri:Area/Ncbi/Checkpoint">002B26</idno><idno type="wicri:Area/Main/Merge">002296</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:10-0376232</idno><idno type="wicri:Area/PascalFrancis/Corpus">000A22</idno><idno type="wicri:Area/PascalFrancis/Curation">002297</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000C12</idno><idno type="wicri:doubleKey">0885-3185:2010:Ku S:age:of:parkinson</idno><idno type="wicri:Area/Main/Merge">002799</idno><idno type="wicri:Area/Main/Curation">001E60</idno><idno type="wicri:Area/Main/Exploration">001E60</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Age of Parkinson's disease onset as a predictor for the development of dyskinesia</title><author><name sortKey="Ku, Stephen" sort="Ku, Stephen" uniqKey="Ku S" first="Stephen" last="Ku">Stephen Ku</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Medicine, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease Research, Education, and Clinical Center, San Francisco Veterans Affairs Medical Center, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Glass, Graham A" sort="Glass, Graham A" uniqKey="Glass G" first="Graham A." last="Glass">Graham A. Glass</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease Research, Education, and Clinical Center, San Francisco Veterans Affairs Medical Center, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of California, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-07-15">2010-07-15</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1177">1177</biblScope><biblScope unit="page" to="1182">1182</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F598433AF0D9202088154346E0D8C4376AA41E73</idno><idno type="DOI">10.1002/mds.23068</idno><idno type="ArticleID">MDS23068</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Age Factors</term><term>Age of Onset</term><term>Age of onset</term><term>Aged</term><term>Aged, 80 and over</term><term>Dyskinesia</term><term>Dyskinesia, Drug-Induced (diagnosis)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Dyskinesia, Drug-Induced (mortality)</term><term>Female</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Levodopa (adverse effects)</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Parkinsonian Disorders (drug therapy)</term><term>Parkinsonian Disorders (mortality)</term><term>Predictive Value of Tests</term><term>Proportional Hazards Models</term><term>Risk Factors</term><term>age of onset</term><term>dyskinesia</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Age Factors</term><term>Age of Onset</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Predictive Value of Tests</term><term>Proportional Hazards Models</term><term>Risk Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Age apparition</term><term>Dyskinésie</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The risk of developing levodopa‐associated dyskinesia is known to vary inversely with the age of Parkinson's disease onset. This study quantifies dyskinesia risks for different Parkinson's onset ages in a patient population treated at the Parkinson's Disease Research, Education, and Clinical Center at the San Francisco Veterans Affairs Medical Center. Medical records were reviewed to determine age of Parkinson's onset, medication history, and dyskinesia onset. Dyskinesia risks were determined by using Kaplan‐Meier analysis. Cox proportional hazard models were used to compare age groups and to perform multivariate modeling. This study included 109 patients with Parkinson's, 105 of whom had onset of symptoms after 1989. At 5 years of levodopa treatment, the dyskinesia risk for patients with onset age 40–49 was 70%, decreasing to 42% for onset ages 50–59, 33% for onset ages 60–69, and 24% for onset ages 70–79. Pairwise comparisons between the 40–49 age group and the other age groups were statistically significant in time‐to‐event models. After 5 years of levodopa treatment, dyskinesia risks became uniformly high regardless of age of onset. These results suggest it is appropriate to use different baseline dyskinesia risks in clinical decision‐making for patients on the basis of their ages of onset. However, the most significant difference occurs between ages 40–49 and ages 50–79, and if more than 5 years of levodopa therapy are anticipated, dyskinesia risk may have less utility when deciding upon Parkinson's therapy. Drug studies for Parkinson's disease should also take age of Parkinson's onset into account when analyzing dyskinesia outcomes. © 2010 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Ku, Stephen" sort="Ku, Stephen" uniqKey="Ku S" first="Stephen" last="Ku">Stephen Ku</name></region><name sortKey="Glass, Graham A" sort="Glass, Graham A" uniqKey="Glass G" first="Graham A." last="Glass">Graham A. Glass</name><name sortKey="Glass, Graham A" sort="Glass, Graham A" uniqKey="Glass G" first="Graham A." last="Glass">Graham A. Glass</name><name sortKey="Ku, Stephen" sort="Ku, Stephen" uniqKey="Ku S" first="Stephen" last="Ku">Stephen Ku</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E60 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E60 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F598433AF0D9202088154346E0D8C4376AA41E73
|texte= Age of Parkinson's disease onset as a predictor for the development of dyskinesia
}}
| This area was generated with Dilib version V0.6.23. |  |